Why is the CSL share price falling on Wednesday?

The ASX market darling has had little share price movement of late.

| More on:
Two medical researchers in white coats collaborate over a computer screen of data in a medical research laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL has announced a new collaboration and licensing deal with a US company to access next-generation mRNA vaccine technology 
  • The CSL share price is down today in line with the broader healthcare sector 
  • Two CSL directors loaded up on more shares last month 

The CSL Limited (ASX: CSL) share price is slightly lower today, down 0.55% to $281.71 at the time of writing.

Meantime the S&P/ASX 200 Index (ASX: XJO) is up 0.34% to just above 7,000 points.

The market is a mixed bag today with some sectors up and some down. The S&P/ASX 200 Health Care Index (ASX: XHJ) is among those in the red, down 0.2% at the time of writing.

What did CSL announce today?

CSL has announced that it has entered into a new collaboration and licensing agreement.

The agreement is with Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT). It's costing CSL US$200 million upfront with further payments down the track if certain milestones are achieved. The companies have also agreed to profit sharing on future product sales.

Under the terms, CSL will have access to late-stage self-amplifying mRNA vaccine platform technology.

According to the release, Arcturus Therapeutics is developing next-generation mRNA vaccines.

CSL chief operating officer Paul McKenzie said:

This collaboration is an exciting opportunity to complement CSL's own next generation mRNA program with a partner who developed a platform to deliver late stage clinical supplies at scale. These combined capabilities will accelerate our journey in mRNA.

CSL is looking to develop and commercialise enhanced vaccines for the flu as well as 'multi-pathogen pandemic preparedness'.

CSL will have the exclusive licence to Arcturus' mRNA technology for the flu, COVID-19, and other respiratory viral diseases.

The license for multi-pathogen pandemic preparedness is non-exclusive but CSL has the right to make it exclusive at a later date.

The deal is subject to regulatory approvals.

What's next for the CSL share price?

As my colleague Monica reported, the CSL share price fell slightly last month.

The company held its annual general meeting on 12 October. CSL CEO and managing director Paul Perreault told shareholders the company was performing in line with its guidance for FY23.

On 17 October, CSL provided an update on its Vifor business. The company advised it expected more than 10% revenue growth in the medium term. CSL gave a new FY23 net profit after tax before amortisation (NPATA) guidance range of US$2.7 billion to US$2.8 billion, including Vifor sales.

Two company directors loaded up on more CSL shares during October. Non-executive director Alison Watkins AM invested $272,000 and non-executive director Dr Megan Clark AC invested $74,000.

Motley Fool contributor Bronwyn Allen has positions in CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 reasons to buy this quality ASX 200 healthcare share today

A leading expert expects this outperforming ASX 200 healthcare share will keep running hot.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Brokers tip 4 ASX 200 healthcare shares to buy now

Healthcare is a defensive sector that can provide useful cover for investors when the market is volatile.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

How Trump's tariffs have created 'upside potential' for CSL shares

A leading expert says CSL shares are now looking ‘cheap’.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Telix shares crash 8% on US FDA blow

This high-flying stock has been hit with some bad news.

Read more »

A man wakes up happy with a smile on his face and arms outstretched.
Healthcare Shares

ResMed shares jump 8% on strong Q3 update

It was yet another strong quarter from this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX All Ords stock is up 10% on big news

This high-flying stock just can't stop rising. What's going on?

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Telix shares rocket 15% on stellar Q1 sales update

Let's see how the company performed during the three months.

Read more »